MRNA Q2 Deep Dive: Revenue Beat Overshadowed by Lower Guidance and Cost Cuts

Biotechnology company Moderna (NASDAQ:MRNA) announced better-than-expected revenue in Q2 CY2025, but sales fell by 41.1% year on year to $142 million. On the other hand, the company’s full-year revenue guidance of $1.85 billion at the midpoint came in 10.5% below analysts’ estimates. Its non-GAAP loss of $2.13 per share was 29% above analysts’ consensus estimates.

Is now the time to buy MRNA? Find out in our full research report (it’s free).

StockStory’s Take

Moderna’s second quarter results were met with a negative market reaction, as investors focused on both a sharp decline in year-over-year sales and ongoing operational challenges. Management attributed quarterly performance primarily to lower COVID vaccine demand and highlighted that U.S. sales performed above internal expectations due to a stronger spring booster campaign. CEO Stéphane Bancel pointed to significant cost-cutting efforts, including a 35% reduction in combined cost of sales and SG&A, and noted, “We remain highly focused on financial discipline.” The company also announced a 10% workforce reduction to further align its cost structure with current demand.

Looking ahead, Moderna’s revised full-year outlook reflects persistent uncertainty in global vaccination rates and the competitive landscape for respiratory vaccines. Management cited a deferral of U.K. shipments and regulatory timing as drivers of lower guidance. CFO James Mock explained that future revenue will depend on the pace of regulatory approvals and the success of new product launches. Bancel emphasized, “We are focused on executing cost discipline and advancing our late-stage pipeline, with the goal to reach cash breakeven by 2028.”

Key Insights from Management’s Remarks

Management attributed the quarter’s results to lower COVID vaccine volumes, a seasonal demand pattern, and progress on cost reduction, while forward commentary centered on pipeline advancement and additional operational efficiencies.

• COVID vaccine demand softened: The main driver of revenue decline was weaker COVID-19 vaccine uptake, with U.S. sales benefiting from a relatively resilient spring booster campaign, especially among adults over 65.
• Pipeline progress highlighted: Management emphasized positive Phase III data for Moderna’s next-generation COVID vaccine (mNEXSPIKE), new FDA approvals for the RSV vaccine (mRESVIA), and advancing the seasonal flu program, which is key to future product diversification.
• Significant cost reductions enacted: The company reported a 35% year-over-year decrease in combined cost of sales and SG&A, achieved through operational streamlining and a 10% headcount reduction, as part of a broader plan to cut annual operating expenses by over $6 billion through 2027.
• International shipment timing impacts: A shift in the U.K. government’s purchasing schedule pushed expected COVID vaccine revenue from late 2025 into early 2026, highlighting the company’s exposure to the timing of large government contracts.
• Regulatory advances and challenges: While the U.S. saw new product approvals, management noted ongoing uncertainties around regulatory timelines in Australia and Canada, as well as competitive pressures in both vaccination rates and pricing.

Drivers of Future Performance

Moderna’s guidance for the remainder of the year is shaped by the pace of new product launches, global vaccine demand trends, and continued cost-cutting measures.

• Vaccine market uncertainties: Management flagged unpredictability in both U.S. and international vaccination rates and competitive pressures as key risks, noting that shipment timing and government purchasing patterns can significantly affect quarterly results.
• Pipeline-driven revenue diversification: Upcoming regulatory filings for the seasonal flu vaccine, a potential flu-COVID combination vaccine, and progress in late-stage oncology and rare disease programs are expected to broaden Moderna’s revenue base beyond seasonal respiratory products.
• Cost discipline as a strategic priority: The company plans to accelerate reductions in R&D and manufacturing expenses, targeting a $4.2 billion annual cash cost base by 2027, and aims for cash breakeven by 2028, with further cuts possible if demand falls short of projections.

Catalysts in Upcoming Quarters

Looking ahead, our team will closely watch (1) the pace of regulatory approvals and launches for the seasonal flu vaccine and the flu-COVID combination candidate, (2) the readout of Phase III efficacy data for the CMV vaccine and progress in oncology studies, and (3) the company’s execution on additional cost-cutting measures and ability to sustain operational efficiencies. Updates on product uptake in key international markets and further headway in pipeline diversification will also be important markers of success.

Moderna currently trades at $25.79, down from $29.56 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free).

Now Could Be The Perfect Time To Invest In These Stocks

Donald Trump’s April 2025 "Liberation Day" tariffs sent markets into a tailspin, but stocks have since rebounded strongly, proving that knee-jerk reactions often create the best buying opportunities.

The smart money is already positioning for the next leg up. Don’t miss out on the recovery - check out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.